Εκπαιδευτικά προγράμματα
Λίστα αντικειμένων

Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Prophylaxis and management of graft versus host disease after
stem-cell transplantation for haematological malignancies: updated
consensus recommendations of the European Society for Blood and
Marrow Transplantation.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


https://ashpublications.org/blood/article/doi/10.1182/blood.2019003471/430032/Mutational-profile-and-benefit-of-gemtuzumab
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Our clinical practice and SOP for AML elderly just
published.
https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2019003662/429643/Is-There-an-Optimal-Conditioning-for-Older?redirectedFrom=fulltext
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


https://ashpublications.org/blood/article/doi/10.1182/blood.2019002959/430249/Molecular-MRD-status-and-outcome-after
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Λοιμώξεις από JCV και BKV σε
ανοσοκατεσταλμένους ασθενείς.
Presenter: Dr Liga
Participants: Prof.Spyridonidis, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Discrepancies between premortem clinical diagnoses and
postmortem
autopsy diagnoses were evaluated. Of 185 patients who
underwent autopsy, 35 patients (18.8%) had
a total of 41 missed infections. Five
patients (2.7%) had >1 missed infection. Of
the 41 missed infections, 18 (43.9%) were viral,
16 (39.0%) were fungal, 5 (12.2%) were...


We decided a policy change and accorrdigly we write the
new SOP. MM
patients will receive non cryopreserved stem cell
grafts.
Presenter: Prof. Spyridondiis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Verigou


A phase II study if vedo in GvHD prevention was presented.
This is of
major importance since we run the phase III vedo
study.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Verigou


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Verigou


Results of the Prospective Randomized HOVON-96 Trial in
Recipients of
Matched Related and Unrelated Donors were presented in ASH
2019, plenary
session
PTCY is better than CSI standrd treatment
https://ashpublications.org/blood/article-abstract/134/Supplement_1/1/427807/Post-Transplantation-Cyclophosphamide-after?redirectedFrom=fulltext
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Verigou


General principles
- We use the lowest effective dose of prednisone or
methylprednisolone.
- We use topical therapy to supplement systemic treatment. (eg
oral budesonide together with beclomethasone)
-We use follow-up endoscopy to evaluate the response to
treatment in patients with persistent
diarrhea. Absence of clinical or...


NPM1_Spyridonidis_EAE_2019
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Verigou


A paper illustrating the hardle in making decisions in
BMT.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Verigou


Presenter: Dr Liga
Participants: Prof.Spyridonidis, Dr Spyridis, Dr Verigou


